←
David R. Spigel, MD, FASCO141 posts
David R. Spigel, MD, FASCO avatar

David R. Spigel, MD, FASCO

@DavidRSpigel

President and Chief Medical Officer at Sarah Cannon Research Institute | Advancing Therapies Through Clinical Research #Oncology #Healthcare #CancerResearch

◷ Joined March 2011▧ 21 Photos and videos
Zach Klaassen avatar
⟳ David R. Spigel, MD, FASCO retweeted
Zach Klaassen@zklaassen_md·Oct 24

Safety/efficacy of JNJ-6143, a first-in-class RIPTAC in heavily pre-Rxed pts with mCRPC @BGarmezy @urotoday #ESMO26 🚨Ph 1 n=105; RP2D: 50 mg 🚨At 50 mg: - <60% any-grade TRAEs - 77% PSA50; 48% PSA90 - High PSA RR irrespective of HR molecular features - 69% ORR

Post attachmentPost attachmentPost attachmentPost attachment
David R. Spigel, MD, FASCO avatar
David R. Spigel, MD, FASCO@DavidRSpigel·Oct 25

Fantastic discussion!

🎯 #ESMO26 | Excellent discussion by @benlevylungdoc on SARON and PERSEE! Two trials, two important lessons for advanced NSCLC. 🔹 SARON: Consolidative radiotherapy improved PFS and local disease control in oligo metastatic NSCLC, but no OS benefit (HR 0.99). 🔹 PERSEE: Pembrolizumab + chemo met its primary endpoint PFS but not OS though numerically better (not powered for OS) in PD-L1 ≥50% NSCLC. Key messages from @benlevylungdoc : • Oligometastatic disease needs better biological definition, beyond the number of lesions. • Treatment intensification should be guided by better patient selection. • More treatment does not automatically mean better outcomes! - Lower threshold to add chemo to pembro in PD-L1 >50% 👏 A thoughtful discussion with practical implications for our clinics. #ESMOAmbassador #LungCancer #NSCLC

Post attachmentPost attachment
NEJM avatar
⟳ David R. Spigel, MD, FASCO retweeted
NEJM@NEJM·Oct 25

Presented at #ESMO26: Among patients with PD-L1–negative advanced nonsquamous non–small-cell lung cancer, progression-free survival was longer with sacituzumab tirumotecan plus pembrolizumab than with chemotherapy plus pembrolizumab (15.0 vs. 5.7 months). Full phase 3 OptiTROP-Lung06 trial results: nej.md/4Bo3liu @myESMO

Post attachment
NEJM avatar
⟳ David R. Spigel, MD, FASCO retweeted
NEJM@NEJM·Oct 25

Presented at #ESMO26: In patients with previously treated advanced non–small-cell lung cancer with a 𝘒𝘙𝘈𝘚 G12C mutation, median progression-free survival was 9.8 months with the KRAS G12C inhibitor divarasib and 5.7 months with sotorasib or adagrasib. Full phase 3 Krascendo 1 trial results: nej.md/4BiCvbk @myESMO

Post attachment
Sarah Cannon Docs avatar
⟳ David R. Spigel, MD, FASCO retweeted
Sarah Cannon Docs@SarahCannonDocs·Oct 21

Expanding access to clinical trials remains a critical priority in oncology research. @SPremji7866 of SCRI recently shared insights with @TargetedOnc on the importance of community-based research and the evolving breast cancer landscape. targetedonc.com/view/dr-prem…

Sarah Cannon Docs avatar
⟳ David R. Spigel, MD, FASCO retweeted
Sarah Cannon Docs@SarahCannonDocs·Oct 22

Congratulations to @IMFmyeloma on the launch of the US Myeloma Network! We are honored to serve as the CRO and support clinical trials designed to advance research and expand opportunities for patients w/ multiple myeloma. Looking forward to this collaboration in #CancerResearch.

I am proud to announce the launch of the US Myeloma Network (USMN) by the International Myeloma Foundation. @IMFmyeloma The USMN will conduct clinical trials including phase III randomized controlled trials. @JNJInnovMed is our first industry partner. @SarahCannonDocs will be our CRO. @SagarLonialMD @TomMartinMD @szusmani @myelomaMD @NikhilMunshiMD prnewswire.com/news-releases…

Sarah Cannon Docs avatar
⟳ David R. Spigel, MD, FASCO retweeted
Sarah Cannon Docs@SarahCannonDocs·Aug 21

In a recent interview w/ @Blood_Cancers, Dr. Hans Lee of @SCRIOncology discusses how cellular therapies are changing care for patients with advanced multiple myeloma and the importance of expanding access. Read the Q&A:

The next step in advanced #myeloma is improving access to therapies such as CAR-T and bispecific antibodies, according to Hans Lee, MD, of @SarahCannonDocs. 📖 Read more from this exclusive Q&A: buff.ly/5qX7rQu

Post attachment
CancerTherapyAdvisor avatar
⟳ David R. Spigel, MD, FASCO retweeted
CancerTherapyAdvisor@CancerTherAdvsr·May 31

Breaking from #ASCO26: The Phase 3 #frontMIND trial successfully hit its primary endpoint! 🚨 Adding tafasitamab + lenalidomide to standard R-CHOP significantly improves PFS in newly diagnosed high-risk #DLBCL. Full story: bit.ly/3REcctU

1:02
Sarah Cannon Docs avatar
⟳ David R. Spigel, MD, FASCO retweeted
Sarah Cannon Docs@SarahCannonDocs·May 28

What research is generating buzz heading into #ASCO26? In a new @biospace feature, Dr. @MeredithPelster of Sarah Cannon Research Institute shares insights on promising advances in pancreatic cancer research and targeted therapies. biospace.com/drug-developmen…